News Search Results
Jun 25, 2025, 14:00 ET Sun Pharma Announces Appointment of Richard Ascroft as CEO North America
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Jun 24, 2025, 16:11 ET ZEISS Solves Industry Challenges at Tech Days Event
quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and therapy in ophthalmology and microsurgery for its customers. ZEISS also stands for the world's leading lithography optics, which is used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Jun 24, 2025, 10:02 ET Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1)
More news about: Innovent Biologics
Jun 24, 2025, 08:01 ET Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease Candidate
Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmology. 2022 Dec 1;140(12):1181-1192.Baratta RO, Schlumpf E, Del Buono BJ, DeLorey S, Ousler G, Calkins DJ.
More news about: Stuart Therapeutics
Jun 24, 2025, 08:00 ET Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients
Early results of the PER-001 glaucoma clinical trial were reported at the Association of Research in Vision and Ophthalmology (ARVO) annual meeting in May 2025. This initial dataset demonstrated improvement in ocular blood flow, optic nerve
More news about: Perfuse Therapeutics
Jun 24, 2025, 07:00 ET Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
the editorial board of the American Journal of Ophthalmology and is a recipient of the Senior Achievement Award from the American Academy of Ophthalmology. Bart Leroy, MD, PhD, is Professor of Ophthalmology, Ophthalmic Genetics, and Visual Electrophysiology
More news about: Ascidian Therapeutics
Jun 24, 2025, 07:00 ET Vision Innovation Partners Acquires Eye Care of Delaware
in the Mid-Atlantic area. This acquisition marks VIP's 26th add-on since its founding in 2017 and strengthens its growing network of ophthalmology practices. Founded in 1997, Eye Care of Delaware offers eye surgery and related treatments to patients
More news about: Gryphon Investors
Jun 24, 2025, 03:30 ET Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
June 24, 2025 /PRNewswire/ -- Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases, today announces the successful
More news about: Breye Therapeutics
Jun 23, 2025, 08:00 ET THE GLAUCOMA FOUNDATION RECEIVES MAJOR EARMARKED $2.5 MILLION GIFT FROM THE HERBERT SIMON FAMILY FOUNDATION
the work of Alon Harris, MS, PhD, FARVO, an internationally renowned leading clinical scientist in the field of ophthalmology and glaucoma. Dr. Harris's work extends from the development of novel diagnostic and monitoring approaches for managing glaucoma to artificial
More news about: The Glaucoma Foundation
Jun 21, 2025, 21:35 ET Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that multiple exploratory mechanism-of-action (MoA) analyses of mazdutide (investigator-initiated trials)
More news about: Innovent Biologics
Jun 18, 2025, 11:00 ET Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®
Therapeutics, RNA Interference, Antisense Oligonucleotides), By Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, By Geography, And Forecast
More news about: Verified Market Research
Jun 18, 2025, 06:48 ET Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Jun 17, 2025, 12:05 ET AI-Powered CDSS Enhances Patient Safety with Real-World Data
precision and practical applicability in real-world clinical settings. The results also revealed high acceptance rates in specialties such as ophthalmology (96.59%) and obstetrics/gynecology (90.01%), indicating strong applicability. In contrast, lower acceptance rates in neurology (38.54%) and hematology-oncology
More news about: AESOP Technology
Jun 17, 2025, 10:30 ET Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights
Geographical Insights: Based on Type, the medical biomimetics market size is divided into Cardiovascular, Orthopedic, Ophthalmology, Dental, and Others. The healthcare industry sees cardiovascular care as its dominant force while accounting for 34.8% of market share in 2023. The
More news about: The Research Insights
Jun 17, 2025, 02:00 ET Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6
tolerance to residual refractive error,"∫7,11 said Professor Beatrice Cochener-Lamard, Head of the Ophthalmology Department at Brest University Hospital in France.^^^ TECNIS Odyssey IOL is the latest innovation
More news about: Johnson & Johnson Medical Devices Companies
Jun 16, 2025, 09:05 ET Axia Women's Health Appoints Kyle Snook as Chief Executive Officer
access to care, especially for vulnerable populations, make him an excellent fit." Mr. Snook joins Axia from PRISM Vision Group, a leading ophthalmology administrative services organization with over 100 affiliated locations, where he served as Chief Operating Officer. Prior to his time at PRISM,
More news about: Axia Women's Health
Jun 16, 2025, 08:30 ET Constitution Surgery Alliance Announces Strategic Growth Investment From Welsh, Carson, Anderson & Stowe
implementation. The Company currently manages 16 facilities in five states that perform over 100,000 orthopedic, total joint replacement, spine, ophthalmology, ENT, urology and GI procedures annually. With a 46-year history of building businesses and fostering innovation in the healthcare industry,
More news about: Constitution Surgery Alliance
Jun 15, 2025, 22:56 ET Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-OSA) of mazdutide,
More news about: Innovent Biologics
Jun 15, 2025, 19:30 ET Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Jun 13, 2025, 11:03 ET Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Jun 13, 2025, 01:10 ET Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jun 12, 2025, 21:00 ET Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA)
More news about: Innovent Biologics
Jun 12, 2025, 12:01 ET Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information
More news about: Specialised Therapeutics
Jun 11, 2025, 07:46 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Hospital, as well as Chairman of the Chinese Society of Clinical Oncology (CSCO) Radiation Therapy Committee; and Dr. Tao Yong, Director of the Ophthalmology Department at Beijing Chao-yang Hospital, Capital Medical University and one of Beijing's Top Ten Outstanding
More news about: Ping An Healthcare and Technology Company Limited
Jun 11, 2025, 07:32 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Hospital, as well as Chairman of the Chinese Society of Clinical Oncology (CSCO) Radiation Therapy Committee; and Dr. Tao Yong, Director of the Ophthalmology Department at Beijing Chao-yang Hospital, Capital Medical University and one of Beijing's Top Ten Outstanding
More news about: Ping An Healthcare and Technology Company Limited